Free Trial

Entrada Therapeutics (TRDA) Insider Trading & Ownership

Entrada Therapeutics logo
$17.93 +0.16 (+0.90%)
(As of 11/20/2024 ET)

Entrada Therapeutics (NASDAQ:TRDA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
7.59%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$151,226.80
Number Of
Insiders Selling
(Last 12 Months)
4
Amount Of
Insider Selling
(Last 12 Months)
$906,100.84
Get TRDA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Entrada Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

TRDA Insider Buying and Selling by Quarter

Entrada Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2024Natarajan SethuramanInsiderSell2,700$20.04$54,108.00  
11/11/2024Kory James WentworthCFOSell8,637$19.98$172,567.26  
11/11/2024Natarajan SethuramanInsiderSell1,409$20.01$28,194.09  
10/16/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00  
9/26/2024Nathan J DowdenCOOSell847$16.00$13,552.00  
9/9/2024Kory James WentworthCFOSell3,195$14.97$47,829.15  
9/9/2024Natarajan SethuramanInsiderSell2,642$15.09$39,867.78  
9/9/2024Nathan J DowdenCOOSell1,904$15.07$28,693.28  
9/6/2024Natarajan SethuramanInsiderSell600$15.24$9,144.00  
9/6/2024Nathan J DowdenCOOSell399$15.19$6,060.81  
7/15/2024Dipal DoshiCEOSell1,600$17.81$28,496.00  
7/15/2024Natarajan SethuramanInsiderSell638$18.00$11,484.00  
7/12/2024Dipal DoshiCEOSell300$18.00$5,400.00  
7/12/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00  
7/8/2024Kory James WentworthCFOSell1,758$14.95$26,282.10  
6/13/2024Dipal DoshiCEOSell1,000$16.17$16,170.00  
5/20/2024Natarajan SethuramanInsiderSell9,675$15.19$146,963.25  
5/16/2024Dipal DoshiCEOSell1,800$15.00$27,000.00  
5/16/2024Natarajan SethuramanInsiderSell1,000$15.00$15,000.00  
5/8/2024Peter S KimDirectorBuy2,276$14.04$31,955.04  
4/8/2024Peter S KimDirectorBuy2,600$13.57$35,282.00  
3/28/2024Peter S KimDirectorBuy1,512$13.75$20,790.00  
3/25/2024Peter S KimDirectorBuy3,180$13.36$42,484.80  
3/21/2024Peter S KimDirectorBuy704$13.24$9,320.96  
3/19/2024Peter S KimDirectorBuy900$12.66$11,394.00  
2/15/2024Dipal DoshiCEOSell1,000$15.00$15,000.00  
1/16/2024Dipal DoshiCEOSell1,000$15.99$15,990.00  
12/26/2023Kory James WentworthCFOSell94$16.67$1,566.98  
12/22/2023Kory James WentworthCFOSell10,206$15.69$160,132.14  
12/20/2023Dipal DoshiCEOSell1,000$15.00$15,000.00  
(Data available from 1/1/2013 forward)

TRDA Insider Trading Activity - Frequently Asked Questions

The list of insiders at Entrada Therapeutics includes Bros. Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher, and Peter S Kim. Learn more on insiders at TRDA.

7.59% of Entrada Therapeutics stock is owned by insiders. Learn more on TRDA's insider holdings.

The following insider purchased TRDA shares in the last 24 months: Peter S Kim ($151,226.80).

Insiders have purchased a total of 11,172 TRDA shares in the last 24 months for a total of $151,226.80 bought.

The following insiders have sold TRDA shares in the last 24 months: Dipal Doshi ($518,743.50), Kory James Wentworth ($896,565.13), Natarajan Sethuraman ($452,127.12), Nathan J Dowden ($365,434.77), and Nerissa Kreher ($266,748.00).

Insiders have sold a total of 156,448 Entrada Therapeutics shares in the last 24 months for a total of $2,499,618.52 sold.

Entrada Therapeutics Key Executives

  • Mr. Dipal Doshi (Age 48)
    CEO & Director
    Compensation: $968.21k
    3 recent trades
  • Mr. Nathan J. Dowden (Age 53)
    President & COO
    Compensation: $694.3k
    3 recent trades
  • Dr. Natarajan Sethuraman Ph.D. (Age 62)
    Chief Scientific Officer
    Compensation: $694.3k
  • Mr. Kory James Wentworth CPA (Age 45)
    CFO & Treasurer
    3 recent trades
  • Dr. Jared Cohen J.D.
    Ph.D., General Counsel
  • Ms. Kerry Robert M.S.
    Senior Vice President of People
  • Ms. Karla MacDonald
    Chief Corporate Affairs Officer
  • Mr. Kevin Healy Ph.D.
    Senior Vice President of Regulatory Affairs


This page (NASDAQ:TRDA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners